BG105096A - Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders - Google Patents

Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders

Info

Publication number
BG105096A
BG105096A BG105096A BG10509600A BG105096A BG 105096 A BG105096 A BG 105096A BG 105096 A BG105096 A BG 105096A BG 10509600 A BG10509600 A BG 10509600A BG 105096 A BG105096 A BG 105096A
Authority
BG
Bulgaria
Prior art keywords
apnea
disorders
norcisapride
bulimia
treaing
Prior art date
Application number
BG105096A
Other languages
Bulgarian (bg)
English (en)
Inventor
Paul Rubin
Timothy Barberich
Original Assignee
Sepracor, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor, Inc filed Critical Sepracor, Inc
Publication of BG105096A publication Critical patent/BG105096A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG105096A 1998-06-15 2000-12-27 Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders BG105096A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8922498P 1998-06-15 1998-06-15
US12227599P 1999-03-01 1999-03-01
PCT/US1999/013099 WO1999065571A2 (en) 1998-06-15 1999-06-10 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders

Publications (1)

Publication Number Publication Date
BG105096A true BG105096A (en) 2002-02-28

Family

ID=26780365

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105096A BG105096A (en) 1998-06-15 2000-12-27 Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders

Country Status (26)

Country Link
US (4) US6048879A (hu)
EP (1) EP1089733B1 (hu)
JP (1) JP2002518352A (hu)
KR (3) KR20060017570A (hu)
CN (1) CN1312717A (hu)
AR (1) AR019671A1 (hu)
AT (1) ATE291427T1 (hu)
AU (1) AU4433399A (hu)
BG (1) BG105096A (hu)
BR (1) BR9911299A (hu)
CA (1) CA2333666A1 (hu)
CZ (1) CZ20004737A3 (hu)
DE (1) DE69924375T2 (hu)
ES (1) ES2237110T3 (hu)
HK (1) HK1040058A1 (hu)
HU (1) HUP0102203A3 (hu)
IL (1) IL140118A0 (hu)
IS (1) IS5756A (hu)
NO (1) NO20006357L (hu)
NZ (3) NZ526943A (hu)
PL (1) PL345275A1 (hu)
PT (1) PT1089733E (hu)
SI (1) SI1089733T1 (hu)
SK (1) SK19052000A3 (hu)
TR (7) TR200003708T2 (hu)
WO (1) WO1999065571A2 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
US7160898B2 (en) 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
TR200103757T2 (tr) 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
JP2002538102A (ja) * 1999-03-01 2002-11-12 セプラコア インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
EP1435238A1 (en) * 1999-03-01 2004-07-07 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040172084A1 (en) * 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7444183B2 (en) * 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US7844338B2 (en) * 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US7803195B2 (en) * 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US7833279B2 (en) * 2004-11-12 2010-11-16 Enteromedics Inc. Pancreatic exocrine secretion diversion apparatus and method
CA2590802A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
US20070233204A1 (en) 2006-02-16 2007-10-04 Lima Marcelo G RFID-based apparatus, system, and method for therapeutic treatment of a patient
US20100198103A1 (en) 2007-10-09 2010-08-05 Imthera Medical, Inc. System and method for neural stimulation
US8428725B2 (en) 2008-10-09 2013-04-23 Imthera Medical, Inc. Method of stimulating a Hypoglossal nerve for controlling the position of a patient's tongue
AU2010318651A1 (en) 2009-11-10 2012-05-03 Imthera Medical, Inc. System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US10123896B2 (en) 2014-03-06 2018-11-13 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) * 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4598123A (en) * 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) * 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) * 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1993012785A1 (en) * 1991-12-21 1993-07-08 Smithkline Beecham Plc Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US5502067A (en) * 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
US5407953A (en) * 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
DK1000029T3 (da) * 1997-07-11 2004-02-23 Janssen Pharmaceutica Nv Norcisaprid nyttig med hensyn til 5-HT3- og 5-HT4- medierede lidelser

Also Published As

Publication number Publication date
NZ508824A (en) 2003-10-31
TR200103058T2 (tr) 2002-06-21
PT1089733E (pt) 2005-08-31
CZ20004737A3 (cs) 2001-10-17
HUP0102203A2 (hu) 2001-11-28
TR200103059T2 (tr) 2002-06-21
KR20060067986A (ko) 2006-06-20
TR200103057T2 (tr) 2002-06-21
KR20010052739A (ko) 2001-06-25
TR200103056T2 (tr) 2002-06-21
US6048879A (en) 2000-04-11
WO1999065571A2 (en) 1999-12-23
EP1089733A2 (en) 2001-04-11
US6835740B2 (en) 2004-12-28
ES2237110T3 (es) 2005-07-16
NZ526943A (en) 2004-11-26
NZ535135A (en) 2006-04-28
BR9911299A (pt) 2001-03-13
US20020147220A1 (en) 2002-10-10
CA2333666A1 (en) 1999-12-23
AU4433399A (en) 2000-01-05
KR20060017570A (ko) 2006-02-23
PL345275A1 (en) 2001-12-03
WO1999065571A3 (en) 2000-04-20
IL140118A0 (en) 2002-02-10
HUP0102203A3 (en) 2001-12-28
DE69924375T2 (de) 2005-08-11
NO20006357L (no) 2001-02-13
TR200103055T2 (tr) 2002-06-21
TR200003708T2 (tr) 2001-06-21
SI1089733T1 (en) 2005-06-30
CN1312717A (zh) 2001-09-12
JP2002518352A (ja) 2002-06-25
IS5756A (is) 2000-12-08
TR200103054T2 (tr) 2002-06-21
AR019671A1 (es) 2002-03-13
HK1040058A1 (zh) 2002-05-24
EP1089733B1 (en) 2005-03-23
ATE291427T1 (de) 2005-04-15
DE69924375D1 (de) 2005-04-28
US6369079B1 (en) 2002-04-09
US20050154018A1 (en) 2005-07-14
SK19052000A3 (sk) 2001-06-11
NO20006357D0 (no) 2000-12-13

Similar Documents

Publication Publication Date Title
BG105096A (en) Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PL316658A1 (en) Novel application of serotonin antagonists
EP1695983A3 (en) Glucagon-like peptide-1 analogs
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
AU3111695A (en) Substituted pyrimidine compounds and the use thereof
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
RS20050199A (en) Imidazolopyridines and methods of making and using the same
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
AU3111595A (en) The use of thiazole and thiadiazole compounds
SE9502921D0 (sv) New compounds
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
BG105097A (en) Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders
AU2634597A (en) Compounds with growth hormone releasing properties
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
MY141020A (en) Novel pparalpha and ppargamma agonists
AU9157698A (en) Piperazine derivatives active on the lower urinary tract
WO2000010554A3 (en) Methods and compositions employing optically pure s(+) vigabatrin
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP1468685A3 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
AU3822900A (en) Process for the treatment of fly ash, using hydrochloric acid
AU2182800A (en) Use of inhibitors of gag synthesis for the treatment of corneal haze
WO2001008668A3 (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders